Wednesday, December 6, 2023 |

Emergent BioSolutions to begin ‘improvements’ at Baltimore facility as J&J evaluates Covid vaccine demand

February 28, 2022

Gaithersburg’s Emergent BioSolutions Inc. (NYSE: EBS) plans to begin “facility improvements” at its Baltimore manufacturing plant as Johnson & Johnson (NYSE: JNJ) assesses demand for its Covid-19 vaccine, which Emergent has been producing at that site. That’s what Emergent President and CEO Bob Kramer told analysts and investors on a fourth-quarter company earnings call Thursday.

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.